GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1

Shen, Chih-Lung; Huang, Wei-Han; Hsu, Hao-Jen; Yang, Jen-Hone; Peng, Chih‐Wen

doi:10.1016/j.antiviral.2019.02.015

Cited by 3 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GAP31 (gelonium anti-HIV protein, 31 kDa) protein, first isolated from the plant Gelonium multifloru , has shown great antiviral activities against HIV and HPV 1 infection [ 130 ]. The authors also reported the antiviral activities of GAP31 (synthetic) against EBV via targeting EBNA1 , the only latent gene expressed in most EBV neoplasms [ 131 ]. EBNA1 binds to the replication origin (oriP) to display its biological impact on EBV-driven cell transformation and maintenance [ 131 ].…”

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%

“…The authors also reported the antiviral activities of GAP31 (synthetic) against EBV via targeting EBNA1 , the only latent gene expressed in most EBV neoplasms [ 131 ]. EBNA1 binds to the replication origin (oriP) to display its biological impact on EBV-driven cell transformation and maintenance [ 131 ]. Recombinant GAP31 blocked EBNA1 dimer formation and consequently impaired EBNA1/oriP binding and transcription [ 131 ].…”

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%

“…EBNA1 binds to the replication origin (oriP) to display its biological impact on EBV-driven cell transformation and maintenance [ 131 ]. Recombinant GAP31 blocked EBNA1 dimer formation and consequently impaired EBNA1/oriP binding and transcription [ 131 ]. The blocking effect of GAP31 on EBNA1 /oriP-dependent functions included impairing EBV-driven cell proliferation, transformation, and tumorigenesis [ 131 ].…”

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%

“…Recombinant GAP31 blocked EBNA1 dimer formation and consequently impaired EBNA1/oriP binding and transcription [ 131 ]. The blocking effect of GAP31 on EBNA1 /oriP-dependent functions included impairing EBV-driven cell proliferation, transformation, and tumorigenesis [ 131 ]. In particular, rGAP31 at 0.32 nM reduced approximately 90% of the lymphoblastoid cell lines proliferation by day 15 in that study [ 131 ].…”

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%

“…The blocking effect of GAP31 on EBNA1 /oriP-dependent functions included impairing EBV-driven cell proliferation, transformation, and tumorigenesis [ 131 ]. In particular, rGAP31 at 0.32 nM reduced approximately 90% of the lymphoblastoid cell lines proliferation by day 15 in that study [ 131 ]. Furthermore, the EBV-driven cell transformation outgrowth was entirely abrogated by 0.64 nM rGAP31 [ 131 ].…”

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%

See 4 more Smart Citations

The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond

Eladwy

Shah

et al. 2023

IJMS

View full text Add to dashboard Cite

Despite recent advances in oncology, cancer has remained an enormous global health burden, accounting for about 10 million deaths in 2020. A third of the cancer cases in developing counties are caused by microbial infections such as human papillomavirus (HPV), Epstein-Barr Virus (EBV), and hepatitis B and C viruses. EBV, a member of the human gamma herpesvirus family, is a double-stranded DNA virus and the primary cause of infectious mononucleosis. Most EBV infections cause no long-term complications. However, it was reported that EBV infection is responsible for around 200,000 malignancies worldwide every year. Currently, there are no vaccines or antiviral drugs for the prophylaxis or treatment of EBV infection. Recently, the gut microbiota has been investigated for its pivotal roles in pathogen protection and regulating metabolic, endocrine, and immune functions. Several studies have investigated the efficacy of antiviral agents, gut microbial metabolites, and natural products against EBV infection. In this review, we aim to summarise and analyse the reported molecular mechanistic and clinical studies on the activities of gut microbial metabolites and natural medicines against carcinogenic viruses, with a particular emphasis on EBV. Gut microbial metabolites such as short-chain fatty acids were reported to activate the EBV lytic cycle, while bacteriocins, produced by Enterococcus durans strains, have shown antiviral properties. Furthermore, several natural products and dietary bioactive compounds, such as curcumin, epigallocatechin gallate, resveratrol, moronic acid, and andrographolide, have shown antiviral activity against EBV. In this review, we proposed several exciting future directions for research on carcinogenic viruses.

show abstract

Section: Natural Products As Antiviral Agents Against Ebvmentioning

confidence: 99%